Libanova, Becker and Carlos.pdf
Open Access publication
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractThe implementation of vaccination as an empiric strategy to protect against infectious diseases was introduced even before the advent of hygiene and antimicrobials in the medical practice. Nevertheless, it was not until a few decades ago that we really started understanding the underlying mechanisms of protection triggered by vaccination. Vaccines were initially based on attenuated or inactivated organisms. Subunit vaccines were then introduced as more refined formulations, exhibiting improved safety profiles. However, purified antigens tend to be poorly immunogenic and often require the use of adjuvants to achieve adequate stimulation of the immune system. Vaccination strategies, such as mucosal administration, also require potent adjuvants to improve performance. In the 1990s, immunologists found that pathogens could be sensed as 'danger signals' by receptors recognizing conserved motifs. Although our knowledge is still limited, tremendous advances were made in the understanding of host defence mechanisms regulated by these evolutionary conserved receptors, and the molecular structures which are recognized by them. This opened a new era in adjuvant development. Some of the latest players arrived to this field are the cyclic di-nucleotides, which are ubiquitous prokaryotic intracellular signalling molecules. This review is focused on their potential for the development of vaccines and immunotherapies.
CitationCyclic di-nucleotides: new era for small molecules as adjuvants. 2012, 5 (2):168-76 Microb Biotechnol
AffiliationHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
- Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.
- Authors: Moyle PM
- Issue date: 2017 May-Jun
- Vaccine adjuvants: smart components to boost the immune system.
- Authors: Bastola R, Noh G, Keum T, Bashyal S, Seo JE, Choi J, Oh Y, Cho Y, Lee S
- Issue date: 2017 Nov
- Adjuvants: Classification, Modus Operandi, and Licensing.
- Authors: Apostólico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS
- Issue date: 2016
- Unmet needs in modern vaccinology: adjuvants to improve the immune response.
- Authors: Leroux-Roels G
- Issue date: 2010 Aug 31
- Intranasal formulations: promising strategy to deliver vaccines.
- Authors: Riese P, Sakthivel P, Trittel S, Guzmán CA
- Issue date: 2014 Oct